Compare LMRI & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMRI | IMTX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2025 | 2020 |
| Metric | LMRI | IMTX |
|---|---|---|
| Price | $11.72 | $9.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $20.75 | $19.00 |
| AVG Volume (30 Days) | 453.7K | ★ 564.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $5.61 | $25.91 |
| P/E Ratio | $235.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.45 | $5.67 |
| 52 Week High | $19.45 | $12.41 |
| Indicator | LMRI | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 54.21 |
| Support Level | $10.09 | $9.37 |
| Resistance Level | $12.81 | $10.55 |
| Average True Range (ATR) | 0.56 | 0.44 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 64.31 | 80.94 |
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.